نتایج جستجو برای: tp53 mutation and expression

تعداد نتایج: 16973495  

Journal: :Human mutation 1997
R S Cornelis M van Vliet M J van de Vijver H F Vasen P A Voute B Top P M Khan P Devilee C J Cornelisse

Three germline mutations in the TP53 tumor-suppressor gene are reported, two of which are not reported previously. A missense mutation at codon 265 of TP53 was found in three patients of a family that complied with the definition of the Li-Fraumeni syndrome. A nonsense mutation in codon 306 was found in a woman who had had a rhabdomyosarcoma at age 4 and a subsequent breast cancer at age 22. Sh...

Journal: :Cancer genetics and cytogenetics 2008
Kanokkan Bumroongkit Bruce Rannala Patrinee Traisathit Metawee Srikummool Yannawan Wongchai Daoroong Kangwanpong

TP53 mutations are observed in about 40-70% of lung cancer tissues, and the hot spot codon mutations are in exons 5 through 8. Previous studies revealed that the distinct TP53 mutational pattern between population groups may be due to different racial or exogenous factors. This research aims to identify risk factors that influence TP53 gene mutation in lung cancer patients residing areas with h...

Journal: :Journal of pediatric hematology/oncology 2003
Ana Patiño-García Elena Sotillo Piñeiro Marta Zalacaín Díez Leire Gárate Iturriagagoitia Federico Antillón Klüssmann Luis Sierrasesúmaga Ariznabarreta

PURPOSE To analyze the genetic and epigenetic alterations affecting the RB1, TP53, p16INK4, and p21WAF1 tumor suppressor genes, loss of heterozygosity (LOH) at 3q and 18q, and the clinical variables of a series of Spanish children with osteosarcoma. These genetic changes were tested for an association with prognosis. METHODS Peripheral blood samples and clinical data were available from 76 pa...

2016
Doris Helbig Michaela Angelika Ihle Katharina Pütz Iliana Tantcheva-Poor Cornelia Mauch Reinhard Büttner Alexander Quaas

BACKGROUND Until now, almost nothing is known about the tumorigenesis of atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS). Our hypothesis is that AFX is the non-infiltrating precursor lesion of PDS. MATERIALS AND METHODS We performed the world-wide most comprehensive immunohistochemical and mutational analysis in well-defined AFX (n=5) and PDS (n=5). RESULTS In NGS-based mu...

2001
Andrew R. Pettitt Paul D. Sherrington Grant Stewart John C. Cawley A. Malcolm R. Taylor Tatjana Stankovic

The well-established association between TP53 mutations and adverse clinical outcome in a range of human cancers reflects the importance of p53 protein in regulating tumor-cell growth and survival. Although it is theoretically possible for p53 dysfunction to arise through mechanisms that do not involve TP53 mutation, such a phenomenon has not previously been demonstrated in a sporadic tumor. He...

Journal: :Lung Cancer 2021

BackgroundNon-small cell lung cancer (NSCLC) patients with high expression of PDL1 are more likely to benefit from atezolizumab. There no relevant research focusing on the relationship between and clinical variables gene mutation types among NSCLC patients.MethodsNSCLC confirmed information OAK study were included in our study. Logistic regression proportional model was applied analyze risk fac...

پایان نامه :وزارت علوم، تحقیقات و فناوری - دانشگاه شیراز - دانشکده حقوق و علوم سیاسی 1390

the author intend to by studying the historical causes of the appearance of the novation in the west and explanation of its legal nature from past to present of french law, proves on the one hand that the novation does not extracted from the french civil code and in the shiite jurisprudence with quite similar terms even before the enactment of iranian civil code, was considered by the shiite su...

Journal: :Blood 2012
Zijun Y Xu-Monette Lin Wu Carlo Visco Yu Chuan Tai Alexander Tzankov Wei-min Liu Santiago Montes-Moreno Karen Dybkaer April Chiu Attilio Orazi Youli Zu Govind Bhagat Kristy L Richards Eric D Hsi X Frank Zhao William W L Choi Xiaoying Zhao J Han van Krieken Qin Huang Jooryung Huh Weiyun Ai Maurilio Ponzoni Andrés J M Ferreri Fan Zhou Brad S Kahl Jane N Winter Wei Xu Jianyong Li Ronald S Go Yong Li Miguel A Piris Michael B Møller Roberto N Miranda Lynne V Abruzzo L Jeffrey Medeiros Ken H Young

TP53 mutation is an independent marker of poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL) treated with cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (CHOP) therapy. However, its prognostic value in the rituximab immunochemotherapy era remains undefined. In the present study of a large cohort of DLBCL patients treated with rituximab plus CHOP (R-CHOP), ...

2015
Koji Ando Eiji Oki Hiroshi Saeki Zhao Yan Yasuo Tsuda Gen Hidaka Yuta Kasagi Hajime Otsu Hiroyuki Kawano Hiroyuki Kitao Masaru Morita Yoshihiko Maehara

Immunohistochemistry staining of p53 is a cheap and simple method to detect aberrant function of p53. However, there are some discrepancies between the result of immunohistochemistry staining and mutation analysis. This study attempted to find a new definition of p53 staining by its staining pattern. Immunohistochemistry staining of p53 and TP53 gene mutation analysis were performed in 148 gast...

Journal: :Carcinogenesis 2006
Nathalie Gonin-Laurent Anne Gibaud Mathilde Huygue Sandrine H Lefèvre Morgane Le Bras Laurent Chauveinc Xavier Sastre-Garau François Doz Livia Lumbroso Sylvie Chevillard Bernard Malfoy

The mutagenic properties of ionizing radiation are well known, but the presence of specific mutations in human radiation-induced tumours is not established. We have studied a series of 36 secondary sarcomas arising in the irradiation field of a primary tumour following radiotherapy. The allelic status and the presence of mutations of the TP53 gene were investigated. The mutation pattern was com...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید